Litigation Details for Duchesnay Inc. v. Actavis Laboratories FL, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Duchesnay Inc. v. Actavis Laboratories FL, Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-11-29 |
| Court | District Court, D. Delaware | Date Terminated | 2020-05-14 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 9,089,489; 9,375,404; 9,526,703; 9,937,132 | ||
| Attorneys | Barbara R. Rudolph | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Duchesnay Inc. v. Actavis Laboratories FL, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Duchesnay Inc. v. Actavis Laboratories FL, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-01-09 | 13 | expiration of U.S. Patent Nos. 9,089,489 (“the ’489 patent”), 9,375,404 (“the ’404 patent”), 9,526,703 (“… claim of U.S. Patent Nos. 9,089,489 (“the ’489 patent”), 9,375,404 (“the ’404 patent”), 9,526,703 (“… ’703 patent”), and 9,937,132 (“the ’132 patent”), and that each and every claim of the patent is invalid…applicant for patent. (b) The alleged invention of the ’489 patent was patented or described…applicant for patent. (b) The alleged invention of the ’404 patent was patented or described | External link to document | |
| 2018-11-29 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,089,489; 9,375,404; 9,526,703… 2018 14 May 2020 1:18-cv-01895 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
